Syndax Pharmaceuticals' (SNDX) Revuforj Expansion a Long-term Growth Lever- Stifel
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $44.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "Formal ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
